ClinicalTrials.gg
CompletedNCT01101022Updated Jun 9, 2021Results posted

Safety and Efficacy of SPD489 on Executive Function Behaviors in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

A Phase 4 interventional study of SPD489 and Placebo in ADHD Specifically With Executive Function Impairment, sponsored by Shire. Completed at 39 sites in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2021-06-09.

Sponsored by Shire (part of Takeda) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
161
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity — 1 open to participants now, 1 under way, none of them phase 3. lisdexamfetamine · Attention Deficit Disorder with Hyperactivity.

Enrollment
15th of 51
161 · median 48
Started
2010
with 4 others
Phase 4
23 of 51
none open now
Registered
26th of 51
by date
Lead sponsor
18 of 51
Shire

Among the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity, this one is the 15th largest by enrollment, is one of 5 that started in 2010, is one of 23 in phase 4, and was the 26th registered.

Attention Deficit Disorder with Hyperactivity

1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

1 of the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About lisdexamfetamine

lisdexamfetamine: first FDA approval 2007 (VYVANSE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity, or all of them as a file.
02

Study summary

The primary objective of the study is to evaluate the efficacy of SPD489 compared to placebo on executive function (self-regulation) behaviors in adults with ADHD who report clinically significant impairment of executive function behavior in their everyday environment, as measured by the self-report Behavior Rating Inventory of Executive Function - Adult Version (BRIEF-A) Global Executive Composite (GEC) T-score.

03

Conditions studied

  • ADHD Specifically With Executive Function Impairment
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject must be 18-55 years of age, inclusive at the time of consent.
  2. Subject has an established close relationship of at least 6-months duration before screening (Visit -1) with an informant who will be able to observe and be willing to report on the subject's behavior and symptoms in multiple social settings during the course of the study. Informant is defined as a person who has a domicile relationship with the subject. When applicable, the informant should be the subject's spouse/significant other. Additionally, the informant cannot participate as a subject in the study and can only serve as the informant for a single subject.
  3. Subject has a lifestyle that in the opinion of the Investigator will enable the subject to complete all study testing and requirements defined in the protocol.
  4. Female subjects must have a negative serum beta human chorionic gonadotropin (HCG) pregnancy test at screening (Visit -1) and a negative urine pregnancy test at baseline (Visit 0) and agree to comply with any applicable requirements of the protocol.
  5. Subject meets the , Fourth Edition - Text Revision (DSM-IV-TR) criteria for a primary diagnosis of ADHD (diagnostic code 314.00 and 314.01) established by a comprehensive psychiatric evaluation that reviews DSM-IV-TR criteria with at least 6 of the 9 subtype criteria met. The Adult ADHD Clinical Diagnostic Scale version 1.2 (ACDS v1.2) will be utilized as the diagnostic tool.
  6. Subject has a total score of ≥65 on BRIEF-A GEC T-score by self-report at baseline (Visit 0).
  7. Subject has a total score of ≥28 using the Adult ADHD-RS with prompts at baseline (Visit 0).
  8. Subject must have a minimum level of intellectual functioning as determined by the Investigator at screening (Visit -1).
  9. Subject is able to swallow a capsule.
  10. Subject is willing and able to comply with all the testing and requirements defined in this protocol.
  11. Subject and informant must be able to provide written, personally signed and dated to participate in the study in accordance with the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) Guidelines and applicable regulations before completing any study related procedures.

Exclusion criteria

Exclusion Criteria

  1. Subject has a current comorbid psychiatric disorder that is either controlled with medications prohibited in this study or is uncontrolled and associated with significant symptoms. Prohibited disorders include those associated with diagnoses including but not limited to any severe comorbid Axis II disorder or severe Axis I disorder (such as Post Traumatic Stress Disorder [PTSD], psychosis, bipolar illness, pervasive developmental disorder, severe obsessive compulsive disorder, severe depressive or severe anxiety disorder). Other symptomatic manifestations (such as agitated states) that contraindicate treatment with SPD489 or confound efficacy or safety assessments in the opinion of the examining physician are also prohibited. Comorbid psychiatric diagnoses will be established by the psychiatric evaluation that includes the Structured Clinical Interview for disorders (SCID-I).
  2. Subjects who are currently considered a suicide risk, any subject who has previously made a suicide attempt or those who are currently demonstrating active suicidal ideation.
  3. The subject has a (BMI) of \<18.5 or ≥40.
  4. Subject has a concurrent chronic or acute illness (such as severe allergic rhinitis or an infectious process requiring antibiotics), disability, or other condition that might confound the results of safety assessments administered in the study or that might increase risk to the subject. Similarly, the subject will be excluded if he or she has any additional condition(s) that in the Investigator's opinion would prohibit the subject from completing the study or would not be in the best interest of the subject. This would include any significant illness or unstable medical condition that could lead to difficulty complying with the protocol. Mild, stable asthma is not exclusionary.
  5. Subject has a history of seizures (other than infantile febrile seizures), any tic disorder, a current diagnosis and/or a known family history of Tourette's Disorder.
  6. Subject has known history of symptomatic cardiovascular disease, advanced arteriosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or stroke or other serious cardiac problems that may place them at increased vulnerability to the sympathomimetic effects of a stimulant drug.
  7. Subject has a known family history of sudden cardiac death or ventricular arrhythmia.
  8. Subject has any or clinically significant laboratory abnormality at screening (Visit -1).
  9. Subject has current abnormal thyroid function, defined as abnormal screening thyroid stimulating hormone (TSH) and thyroxine (T4). Treatment with a stable dose of thyroid medication for at least 3 months is permitted.
  10. Subject has a history of moderate to severe hypertension or has a resting sitting systolic blood pressure >139mmHg or diastolic blood pressure >89mmHg. Subjects with well-controlled mild or moderate hypertension on a single antihypertensive agent are allowed. Combination antihypertensive medications are not allowed.
  11. Subject is taking any medication that is excluded.
  12. Subject has a documented allergy, , or intolerance to amphetamines.
  13. Subject has a documented allergy, hypersensitivity, or intolerance to any in the medicinal product.
  14. Subject has failed to respond to one or more adequate courses (dose and duration) of amphetamine therapy.
  15. Subject has a recent history (within the past 6 months) of suspected substance abuse or dependence disorder (excluding nicotine) in accordance with DSM-IV-TR criteria.
  16. Subject has a positive urine drug result at screening (Visit -1) (with the exception of subject's current stimulant therapy, if any).
  17. Subject has taken an investigational drug or taken part in a clinical trial, including an SPD489 clinical trial, within 30 days prior to screening (Visit -1).
  18. Subject has glaucoma.
  19. Subject is taking other medications that have central nervous system (CNS) effects or affect performance, such as sedating antihistamines and decongestant sympathomimetics, or are monoamine oxidase inhibitors (during or within 7 days of investigational medicinal product administration). Stable use of bronchodilator inhalers is not exclusionary.
  20. Subject is female and pregnant or lactating.
  21. Subjects who have previously been randomized into this study and subsequently withdrawn.
  22. Subject is well controlled on their current ADHD medication with acceptable tolerability.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
161 participants (actual)

Study arms

  • Active comparator
    SPD489

    Drug: SPD489

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

  • DrugSPD489

    1 capsule per day (30, 50 or 70 mg), daily throughout the double-blind treatment period (10 weeks)

    Also known as: Vyvanse

  • OtherPlacebo

    1 capsule per day, daily throughout the double-blind treatment period (10 weeks)

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Subject-reported Behavior Rating Inventory of Executive Function - Adult Version Global Executive Composite T-score (BRIEF-A GEC T) at up to 10 Weeks

    BRIEF-A Global Executive Composite assesses behavioral aspects of executive function. Items are rated 1 (never), 2 (sometimes), and 3 (often). There is no range for a total score. Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.

    Time frame: Baseline and up to 10 weeks

Secondary outcomes

  1. Change From Baseline in Adult ADHD Impact Module (AIM-A) Multi-Item Scales Total Score at up to 10 Weeks

    The AIM-A was developed to assess impact of core ADHD symptoms on daily functioning and quality of life. For multi-item scales, subjects respond to items using a Likert scale with responses ranging from 1 (strongly agree) to 5 (strongly disagree). Scores were computed by deriving the mean of the item sets and transforming the scale score on a continuum from 0 to 100 using a standard formula. Higher scores indicate a better quality of life.

    Time frame: Baseline and up to 10 weeks

  2. Change From Baseline in Informant-reported BRIEF-A T-scores at up to 10 Weeks

    BRIEF-A is a validated 75-item questionnaire composed of three indexes (Global Executive Composite, Behavioral Recognition Index, and Metacognition Index). Items are rated 1 (never), 2 (sometimes), and 3 (often). Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.

    Time frame: Baseline and up to10 weeks

  3. Change From Baseline in Subject-reported BRIEF-A T-scores at up to 10 Weeks

    BRIEF-A is a validated 75-item questionnaire composed of three indexes (Global Executive Composite, Behavioral Recognition Index, and Metacognition Index). Global Executive Composite was reported as the Primary Outcome. Items are rated 1 (never), 2 (sometimes), and 3 (often). There is no range for a total score. Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.

    Time frame: Baseline and up to 10 weeks

  4. Change From Baseline in Subject-reported BRIEF-A Clinical Subscales T-scores at up to 10 Weeks

    BRIEF-A clinical subscales items are rated 1 (never), 2 (sometimes), and 3 (often). There is no range for a total score. Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.

    Time frame: Baseline and up to 10 weeks

  5. Change From Baseline in Informant-reported BRIEF-A Clinical Subscales T-scores at up to 10 Weeks

    BRIEF-A clinical subscales items are rated 1 (never), 2 (sometimes), and 3 (often). There is no range for a total score. Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.

    Time frame: Baseline and up to 10 weeks

  6. Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS) With Adult Prompts Total Score at up to 10 Weeks

    The ADHD-RS consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54. Lower scores indicate reduction in symptoms.

    Time frame: Baseline and up to 10 weeks

  7. Percent of Participants With Clinical Global Impression - Severity of Illness (CGI-S) at Baseline

    CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)

    Time frame: Baseline

  8. Percent of Participants With Clinical Global Impression - Severity of Illness (CGI-S) at up to 10 Weeks

    CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)

    Time frame: Up to 10 weeks post-dose

  9. Percent of Participants With Improvement on Clinical Global Impression - Global Improvement (CGI-I) at up to 10 Weeks

    Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.

    Time frame: Up to 10 weeks post-dose

  10. Change From Baseline in AIM-A Multi-Item Scales of Living With ADHD and General Well-being Score at up to 10 Weeks

    The AIM-A was developed to assess impact of core ADHD symptoms on daily functioning and quality of life. For multi-item scales, subjects respond to items using a Likert scale with responses ranging from 1 (strongly agree) to 5 (strongly disagree). Scores were computed by deriving the mean of the item sets and transforming the scale score on a continuum from 0 to 100 using a standard formula. Higher scores indicate a better quality of life.

    Time frame: Baseline and up to 10 weeks

  11. Change From Baseline in AIM-A Quality of Life Questions 1 and 4 Scores at up to 10 Weeks

    Question 1: 'On a scale of 1 to 10, how would you rate the overall quality of life right now?' It is rated on a scale of 1 (worst) to 10 (best). Higher scores representing a more positive rating. Question 4: 'How much do you agree with this statement: Over the past few weeks, I've had more good days than bad days?' This is rated on a scale of 1 (strongly agree) to 5 (strongly disagree). Lower scores represent better quality of life.

    Time frame: Baseline and up to 10 weeks

  12. Change From Baseline in Conner's Adult ADHD Rating Scale-Observer: Short Version (CAARS-O:S) ADHD Index T-score at up to 10 Weeks

    The CAARS-O:S is an assessment tool with prompts provided to an observer who describes ADHD-related symptoms in an adult subject. The 26-item scale is scored on a 4-point scale from 0 (not at all) to 3 (very much, very frequently). There is no range for a total score. Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.

    Time frame: Baseline and up to 10 weeks

  13. Change From Baseline in CAARS-O:S Factor-derived Subscale T-scores at up to 10 Weeks

    The CAARS-O:S is an assessment tool with prompts provided to an observer who describes ADHD-related symptoms in an adult subject. The 26-item scale is scored on a 4-point scale from 0 (not at all) to 3 (very much, very frequently). There is no range for a total score. Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.

    Time frame: Baseline and up to 10 weeks

  14. Change From Baseline in Adult ADHD Quality of Life (AAQoL) Scale Total Score at up to 10 Weeks

    AAQoL is a validated 29-item scale consisting of 4 subscales. The AAQoL yields a total score and 4 subscale scores. Subjects rate each item on a 5-point Likert scale ranging from 1 (not at all/never) to 5 (extremely/very often). These scores are then transformed to a 0-100 point scale with higher scores indicating better quality of life.

    Time frame: Baseline and up to 10 weeks

07

Results

Posted Feb 13, 2012

Participant flow

Participant flow — Overall Study
MilestoneSPD489Placebo
Started7980
Completed6253
Not completed1727
Withdrew: Adverse event62
Withdrew: Protocol violation43
Withdrew: Withdrawal by subject38
Withdrew: Lost to follow-up14
Withdrew: Lack of efficacy07
Withdrew: Sponsor decision11
Withdrew: Non-compliance10
Withdrew: Work schedule11
Withdrew: Vacation01

Outcome measures

PrimaryChange From Baseline in Subject-reported Behavior Rating Inventory of Executive Function - Adult Version Global Executive Composite T-score (BRIEF-A GEC T) at up to 10 Weeks

BRIEF-A Global Executive Composite assesses behavioral aspects of executive function. Items are rated 1 (never), 2 (sometimes), and 3 (often). There is no range for a total score. Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.

Time frame:
Baseline and up to 10 weeks
Reported as:
Least squares mean · T-scores
Change From Baseline in Subject-reported Behavior Rating Inventory of Executive Function - Adult Version Global Executive Composite T-score (BRIEF-A GEC T) at up to 10 Weeks
T-scoresSPD489Placebo
Change From Baseline in Subject-reported Behavior Rating Inventory of Executive Function - Adult Version Global Executive Composite T-score (BRIEF-A GEC T) at up to 10 Weeks-22.3 ± 1.67-11.1 ± 1.72
Statistical analysis
  • SPD489 vs Placebo · ANCOVA · p = <0.0001 · Mean difference (final values): -11.2 · 95% CI -15.9 to -6.4
SecondaryChange From Baseline in Adult ADHD Impact Module (AIM-A) Multi-Item Scales Total Score at up to 10 Weeks

The AIM-A was developed to assess impact of core ADHD symptoms on daily functioning and quality of life. For multi-item scales, subjects respond to items using a Likert scale with responses ranging from 1 (strongly agree) to 5 (strongly disagree). Scores were computed by deriving the mean of the item sets and transforming the scale score on a continuum from 0 to 100 using a standard formula. Higher scores indicate a better quality of life.

Time frame:
Baseline and up to 10 weeks
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Adult ADHD Impact Module (AIM-A) Multi-Item Scales Total Score at up to 10 Weeks
Scores on a scaleSPD489Placebo
Performance and Daily Functioning38.8 ± 2.8417.2 ± 2.91
Impact of symptoms: Daily Interference30.6 ± 2.5215.7 ± 2.58
Impact of symptoms: Bother/Concern29.3 ± 2.5315.8 ± 2.60
Relationships/Communication21.2 ± 2.4913.4 ± 2.56
Statistical analysis
  • SPD489 vs Placebo · ANCOVA · p = <0.0001 · Mean difference (final values): 21.6 · 95% CI 13.5 to 29.7
  • SPD489 vs Placebo · ANCOVA · p = <0.0001 · Mean difference (final values): 14.9 · 95% CI 7.8 to 22.0
  • SPD489 vs Placebo · ANCOVA · p = 0.0003 · Mean difference (final values): 13.5 · 95% CI 6.3 to 20.7
  • SPD489 vs Placebo · ANCOVA · p = 0.0302 · Mean difference (final values): 7.8 · 95% CI 0.8 to 14.9
SecondaryChange From Baseline in Informant-reported BRIEF-A T-scores at up to 10 Weeks

BRIEF-A is a validated 75-item questionnaire composed of three indexes (Global Executive Composite, Behavioral Recognition Index, and Metacognition Index). Items are rated 1 (never), 2 (sometimes), and 3 (often). Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.

Time frame:
Baseline and up to10 weeks
Reported as:
Least squares mean · T-scores
Change From Baseline in Informant-reported BRIEF-A T-scores at up to 10 Weeks
T-scoresSPD489Placebo
Global Executive Composite-10.2 ± 1.06-5.3 ± 1.06
Behavioral Regulation Index-8.6 ± 1.04-5.5 ± 1.04
Metacognition Index-10.3 ± 1.07-4.6 ± 1.07
Statistical analysis
  • SPD489 vs Placebo · ANCOVA · p = 0.0016 · Mean difference (final values): -4.9 · 95% CI -7.8 to -1.9
  • SPD489 vs Placebo · ANCOVA · p = 0.0355 · Mean difference (final values): -3.1 · 95% CI -6.0 to -0.2
  • SPD489 vs Placebo · ANCOVA · p = 0.0003 · Mean difference (final values): -5.7 · 95% CI -8.7 to -2.7
SecondaryChange From Baseline in Subject-reported BRIEF-A T-scores at up to 10 Weeks

BRIEF-A is a validated 75-item questionnaire composed of three indexes (Global Executive Composite, Behavioral Recognition Index, and Metacognition Index). Global Executive Composite was reported as the Primary Outcome. Items are rated 1 (never), 2 (sometimes), and 3 (often). There is no range for a total score. Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.

Time frame:
Baseline and up to 10 weeks
Reported as:
Mean · T-scores
Change From Baseline in Subject-reported BRIEF-A T-scores at up to 10 Weeks
T-scoresSPD489Placebo
Behavioral Regulation Index-17.5 ± 1.54-9.2 ± 1.58
Metacognition Index-22.8 ± 1.63-11.2 ± 1.67
Statistical analysis
  • SPD489 vs Placebo · ANCOVA · p = 0.0002 · Mean difference (final values): -8.4 · 95% CI -12.7 to -4.0
  • SPD489 vs Placebo · ANCOVA · p = <0.0001 · Mean difference (final values): -11.6 · 95% CI -16.3 to -7.0
SecondaryChange From Baseline in Subject-reported BRIEF-A Clinical Subscales T-scores at up to 10 Weeks

BRIEF-A clinical subscales items are rated 1 (never), 2 (sometimes), and 3 (often). There is no range for a total score. Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.

Time frame:
Baseline and up to 10 weeks
Reported as:
Least squares mean · T-scores
Change From Baseline in Subject-reported BRIEF-A Clinical Subscales T-scores at up to 10 Weeks
T-scoresSPD489Placebo
Inhibit-17.8 ± 1.50-9.5 ± 1.54
Shift-14.5 ± 1.46-7.8 ± 1.50
Emotional control-10.9 ± 1.28-5.7 ± 1.31
Self-monitor-16.6 ± 1.44-8.4 ± 1.48
Initiate-17.9 ± 1.38-8.6 ± 1.41
Working memory-23.2 ± 1.67-11.9 ± 1.71
Plan/Organize-20.8 ± 1.58-9.9 ± 1.62
Task monitor-20.1 ± 1.64-10.8 ± 1.68
Organization of materials-16.5 ± 1.26-7.6 ± 1.30
Statistical analysis
  • SPD489 vs Placebo · ANCOVA · p = 0.0001 · Mean difference (final values): -8.3 · 95% CI -12.6 to -4.1
  • SPD489 vs Placebo · ANCOVA · p = 0.0018 · Mean difference (final values): -6.7 · 95% CI -10.8 to -2.5
  • SPD489 vs Placebo · ANCOVA · p = 0.0056 · Mean difference (final values): -5.2 · 95% CI -8.8 to -1.5
  • SPD489 vs Placebo · ANCOVA · p = 0.0001 · Mean difference (final values): -8.2 · 95% CI -12.3 to -4.1
  • SPD489 vs Placebo · ANCOVA · p = <0.0001 · Mean difference (final values): -9.3 · 95% CI -13.2 to -5.4
  • SPD489 vs Placebo · ANCOVA · p = <0.0001 · Mean difference (final values): -11.3 · 95% CI -16.0 to -6.6
  • SPD489 vs Placebo · ANCOVA · p = <0.0001 · Mean difference (final values): -10.9 · 95% CI -15.4 to -6.4
  • SPD489 vs Placebo · ANCOVA · p = 0.0001 · Mean difference (final values): -9.3 · 95% CI -14.0 to -4.7
  • SPD489 vs Placebo · ANCOVA · p = <0.0001 · Mean difference (final values): -8.9 · 95% CI -12.5 to -5.3
SecondaryChange From Baseline in Informant-reported BRIEF-A Clinical Subscales T-scores at up to 10 Weeks

BRIEF-A clinical subscales items are rated 1 (never), 2 (sometimes), and 3 (often). There is no range for a total score. Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.

Time frame:
Baseline and up to 10 weeks
Reported as:
Least squares mean · T-scores
Change From Baseline in Informant-reported BRIEF-A Clinical Subscales T-scores at up to 10 Weeks
T-scoresSPD489Placebo
Inhibit-10.2 ± 1.08-5.8 ± 1.08
Shift-9.1 ± 1.17-4.3 ± 1.17
Emotional control-5.9 ± 0.99-4.6 ± 0.99
Self-monitor-6.8 ± 1.04-4.6 ± 1.04
Initiate-8.6 ± 1.00-3.2 ± 1.00
Working memory-12.0 ± 1.22-5.7 ± 1.22
Plan/Organize-9.9 ± 1.07-5.0 ± 1.07
Task monitor-9.7 ± 1.21-3.4 ± 1.21
Organization of materials-6.2 ± 0.97-3.0 ± 0.97
Statistical analysis
  • SPD489 vs Placebo · ANCOVA · p = 0.0048 · Mean difference (final values): -4.4 · 95% CI -7.4 to -1.4
  • SPD489 vs Placebo · ANCOVA · p = 0.0045 · Mean difference (final values): -4.8 · 95% CI -8.0 to -1.5
  • SPD489 vs Placebo · ANCOVA · p = 0.3605 · Mean difference (final values): -1.3 · 95% CI -4.0 to 1.5
  • SPD489 vs Placebo · ANCOVA · p = 0.1468 · Mean difference (final values): -2.2 · 95% CI -5.1 to 0.8
  • SPD489 vs Placebo · ANCOVA · p = 0.0002 · Mean difference (final values): -5.5 · 95% CI -8.3 to -2.7
  • SPD489 vs Placebo · ANCOVA · p = 0.0004 · Mean difference (final values): -6.3 · 95% CI -9.8 to -2.9
  • SPD489 vs Placebo · ANCOVA · p = 0.0015 · Mean difference (final values): -4.9 · 95% CI -7.9 to -1.9
  • SPD489 vs Placebo · ANCOVA · p = 0.0003 · Mean difference (final values): -6.3 · 95% CI -9.7 to -2.9
  • SPD489 vs Placebo · ANCOVA · p = 0.0234 · Mean difference (final values): -3.2 · 95% CI -5.9 to -0.4
SecondaryChange From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS) With Adult Prompts Total Score at up to 10 Weeks

The ADHD-RS consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54. Lower scores indicate reduction in symptoms.

Time frame:
Baseline and up to 10 weeks
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS) With Adult Prompts Total Score at up to 10 Weeks
Scores on a scaleSPD489Placebo
Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS) With Adult Prompts Total Score at up to 10 Weeks-21.4 ± 1.35-10.3 ± 1.38
Statistical analysis
  • SPD489 vs Placebo · ANCOVA · p = <0.0001 · Mean difference (final values): -11.1 · 95% CI -14.9 to -7.3
SecondaryPercent of Participants With Clinical Global Impression - Severity of Illness (CGI-S) at Baseline

CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)

Time frame:
Baseline
Reported as:
Number · Percent of participants
Percent of Participants With Clinical Global Impression - Severity of Illness (CGI-S) at Baseline
Percent of participantsSPD489Placebo
Normal, not at all ill00
Borderline mentally ill00
Mildly ill00
Moderately ill48.142.7
Markedly ill38.049.3
Severely ill13.98.0
Among the most extremely ill00
SecondaryPercent of Participants With Clinical Global Impression - Severity of Illness (CGI-S) at up to 10 Weeks

CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)

Time frame:
Up to 10 weeks post-dose
Reported as:
Number · Percent of participants
Percent of Participants With Clinical Global Impression - Severity of Illness (CGI-S) at up to 10 Weeks
Percent of participantsSPD489Placebo
Normal, not at all ill13.96.7
Borderline mentally ill38.016.0
Mildly ill21.510.7
Moderately ill15.237.3
Markedly ill8.925.3
Severely ill2.54.0
Among the most extremely ill00
SecondaryPercent of Participants With Improvement on Clinical Global Impression - Global Improvement (CGI-I) at up to 10 Weeks

Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.

Time frame:
Up to 10 weeks post-dose
Reported as:
Number · Percent of participants
Percent of Participants With Improvement on Clinical Global Impression - Global Improvement (CGI-I) at up to 10 Weeks
Percent of participantsSPD489Placebo
Percent of Participants With Improvement on Clinical Global Impression - Global Improvement (CGI-I) at up to 10 Weeks78.534.7
Statistical analysis
  • SPD489 vs Placebo · Chi-squared · p = <0.0001
SecondaryChange From Baseline in AIM-A Multi-Item Scales of Living With ADHD and General Well-being Score at up to 10 Weeks

The AIM-A was developed to assess impact of core ADHD symptoms on daily functioning and quality of life. For multi-item scales, subjects respond to items using a Likert scale with responses ranging from 1 (strongly agree) to 5 (strongly disagree). Scores were computed by deriving the mean of the item sets and transforming the scale score on a continuum from 0 to 100 using a standard formula. Higher scores indicate a better quality of life.

Time frame:
Baseline and up to 10 weeks
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in AIM-A Multi-Item Scales of Living With ADHD and General Well-being Score at up to 10 Weeks
Scores on a scaleSPD489Placebo
Living with ADHD14.0 ± 1.304.9 ± 1.33
General Well-being19.7 ± 1.699.0 ± 1.73
Statistical analysis
  • SPD489 vs Placebo · ANCOVA · p = <0.0001 · Mean difference (final values): 9.1 · 95% CI 5.4 to 12.7
  • SPD489 vs Placebo · ANCOVA · p = <0.0001 · Mean difference (final values): 10.8 · 95% CI 6.0 to 15.5
SecondaryChange From Baseline in AIM-A Quality of Life Questions 1 and 4 Scores at up to 10 Weeks

Question 1: 'On a scale of 1 to 10, how would you rate the overall quality of life right now?' It is rated on a scale of 1 (worst) to 10 (best). Higher scores representing a more positive rating. Question 4: 'How much do you agree with this statement: Over the past few weeks, I've had more good days than bad days?' This is rated on a scale of 1 (strongly agree) to 5 (strongly disagree). Lower scores represent better quality of life.

Time frame:
Baseline and up to 10 weeks
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in AIM-A Quality of Life Questions 1 and 4 Scores at up to 10 Weeks
Scores on a scaleSPD489Placebo
Question 11.6 ± 0.161.0 ± 0.16
Question 4-1.0 ± 0.11-0.4 ± 0.11
Statistical analysis
  • SPD489 vs Placebo · ANCOVA · p = 0.0184 · Mean difference (final values): 0.5 · 95% CI 0.1 to 1.0
  • SPD489 vs Placebo · ANCOVA · p = 0.0004 · Mean difference (final values): -0.6 · 95% CI -0.9 to -0.3
SecondaryChange From Baseline in Conner's Adult ADHD Rating Scale-Observer: Short Version (CAARS-O:S) ADHD Index T-score at up to 10 Weeks

The CAARS-O:S is an assessment tool with prompts provided to an observer who describes ADHD-related symptoms in an adult subject. The 26-item scale is scored on a 4-point scale from 0 (not at all) to 3 (very much, very frequently). There is no range for a total score. Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.

Time frame:
Baseline and up to 10 weeks
Reported as:
Least squares mean · T-scores
Change From Baseline in Conner's Adult ADHD Rating Scale-Observer: Short Version (CAARS-O:S) ADHD Index T-score at up to 10 Weeks
T-scoresSPD489Placebo
Change From Baseline in Conner's Adult ADHD Rating Scale-Observer: Short Version (CAARS-O:S) ADHD Index T-score at up to 10 Weeks-11.3 ± 1.24-5.8 ± 1.24
Statistical analysis
  • SPD489 vs Placebo · ANCOVA · p = 0.0019 · Mean difference (final values): -5.5 · 95% CI -9.0 to -2.1
SecondaryChange From Baseline in CAARS-O:S Factor-derived Subscale T-scores at up to 10 Weeks

The CAARS-O:S is an assessment tool with prompts provided to an observer who describes ADHD-related symptoms in an adult subject. The 26-item scale is scored on a 4-point scale from 0 (not at all) to 3 (very much, very frequently). There is no range for a total score. Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.

Time frame:
Baseline and up to 10 weeks
Reported as:
Least squares mean · T-scores
Change From Baseline in CAARS-O:S Factor-derived Subscale T-scores at up to 10 Weeks
T-scoresSPD489Placebo
Inattention/Memory Problems-10.0 ± 1.12-4.9 ± 1.12
Hyperactivity/Restlessness-9.1 ± 1.20-5.0 ± 1.20
Impulsivity/Emotional Liability-8.0 ± 1.01-4.0 ± 1.01
Problems with Self-concept-7.7 ± 1.10-3.3 ± 1.10
Statistical analysis
  • SPD489 vs Placebo · ANCOVA · p = 0.0017 · Mean difference (final values): -5.1 · 95% CI -8.2 to -1.9
  • SPD489 vs Placebo · ANCOVA · p = 0.0174 · Mean difference (final values): -4.1 · 95% CI -7.5 to -0.7
  • SPD489 vs Placebo · ANCOVA · p = 0.0063 · Mean difference (final values): -4.0 · 95% CI -6.8 to -1.1
  • SPD489 vs Placebo · ANCOVA · p = 0.0059 · Mean difference (final values): -4.4 · 95% CI -7.5 to -1.3
SecondaryChange From Baseline in Adult ADHD Quality of Life (AAQoL) Scale Total Score at up to 10 Weeks

AAQoL is a validated 29-item scale consisting of 4 subscales. The AAQoL yields a total score and 4 subscale scores. Subjects rate each item on a 5-point Likert scale ranging from 1 (not at all/never) to 5 (extremely/very often). These scores are then transformed to a 0-100 point scale with higher scores indicating better quality of life.

Time frame:
Baseline and up to 10 weeks
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Adult ADHD Quality of Life (AAQoL) Scale Total Score at up to 10 Weeks
Scores on a scaleSPD489Placebo
Life Productivity38.0 ± 4.3417.0 ± 4.51
Psychological Health19.3 ± 3.617.2 ± 3.74
Life Outlook18.5 ± 2.856.0 ± 2.96
Relationships17.1 ± 3.699.8 ± 3.83
Total Score25.9 ± 3.0411.1 ± 3.16
Statistical analysis
  • SPD489 vs Placebo · ANCOVA · p = 0.0016 · Mean difference (final values): 21.0 · 95% CI 8.4 to 33.6
  • SPD489 vs Placebo · ANCOVA · p = 0.0242 · Mean difference (final values): 12.1 · 95% CI 1.6 to 22.5
  • SPD489 vs Placebo · ANCOVA · p = 0.0038 · Mean difference (final values): 12.5 · 95% CI 4.2 to 20.8
  • SPD489 vs Placebo · ANCOVA · p = 0.1752 · Mean difference (final values): 7.3 · 95% CI -3.4 to 18.0
  • SPD489 vs Placebo · ANCOVA · p = 0.0015 · Mean difference (final values): 14.7 · 95% CI 5.9 to 23.6

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SPD489—0/79 (0%)62/79 (78.5%)
Placebo—0/80 (0%)41/80 (51.3%)
Most frequent other events
Showing 10 of 17
Most frequent other events
EventSPD489Placebo
Decreased ApetiteMetabolism and nutrition disorders26/795/80
Dry MouthGastrointestinal disorders25/796/80
HeadacheNervous system disorders20/792/80
Feeling JitteryGeneral disorders10/790/80
InsomniaPsychiatric disorders10/793/80
IrritabilityGeneral disorders8/793/80
Weight DecreasedInvestigations8/790/80
Initial InsomniaPsychiatric disorders8/795/80
DiarrheaGastrointestinal disorders6/792/80
FatigueGeneral disorders6/793/80

Baseline characteristics

Age, Continuous
Age, Continuous(years)SPD489PlaceboTotal
Mean34.2 ± 10.5834.9 ± 11.0234.6 ± 10.77
Age, Customized
Age, Customized(Participants)SPD489PlaceboTotal
<18 years000
18 to 55 years7980159
>55 years000
Sex: Female, Male
Sex: Female, Male(Participants)SPD489PlaceboTotal
Female393776
Male404383
Region of Enrollment
Region of Enrollment(Participants)SPD489PlaceboTotal
United States7980159
08

Study locations

39 sites
  • Clinical Study Centers, LLC
    Little Rock, Arkansas 72205, United States
  • Peninsula Research Assoc, Inc
    Rolling Hills Estates, California 90274, United States
  • PCSD Feighner Research
    San Diego, California 92108, United States
  • Florida Clinical Research Center, LLC
    Bradenton, Florida 34208, United States
  • Gulfcoast Clinical Research Center
    Fort Myers, Florida 33912, United States
  • Dr. George Joseph, MD and Associates PA
    Jacksonville Beach, Florida 32250, United States
  • Florida Clinical Research Center, LLC
    Maitland, Florida 32751, United States
  • CNS Healthcare
    Orlando, Florida 32806, United States
  • Janus Center For Psychiatric Research
    West Palm Beach, Florida 33407, United States
  • Atlanta Center For Medical Research
    Atlanta, Georgia 30308, United States
  • Northwest Behavioral Research Center
    Marietta, Georgia 30060, United States
  • Capstone Clinical Research
    Libertyville, Illinois 60048, United States
  • AMR-BABER Research Inc.
    Naperville, Illinois 60563, United States
  • Psychiatric Associates
    Overland Park, Kansas 66211, United States
  • Vince and Associates Clinical Research, Inc.
    Overland Park, Kansas 66211, United States
  • Four Rivers Clinical Research
    Paducah, Kentucky 42003, United States
  • Mark Hertzman MD, PC
    Rockville, Maryland 20852, United States
  • Rochester Center for Behavioral Medicine
    Rochester Hills, Michigan 48307, United States
  • The Behavioral Medicine Clinic of NW Michigan, PC
    Traverse City, Michigan 49686, United States
  • Midwest Research Group
    Saint Charles, Missouri 63301, United States
  • Center for Psychiatry and Behavioral Medicine, Inc.
    Las Vegas, Nevada 89128, United States
  • Center for Emotional Fitness
    Cherry Hill, New Jersey, United States
  • Bioscience Research, LLC
    Mount Kisco, New York 10549, United States
  • Mental Health and Addictive Disorders Research Program
    New York, New York 10016, United States
  • Triangle Neuropsychiatry
    Durham, North Carolina 27707, United States
  • Richard H. Weisler, MD, Pa & Associates
    Raleigh, North Carolina 27609, United States
  • Oregon Center for Clinical Investigations, Inc.
    Portland, Oregon 97210, United States
  • Occi, Inc (Oregon Center For Clinical Investigations, Inc.)
    Salem, Oregon 97301, United States
  • FutureSearch Trials, LP
    Austin, Texas 78756, United States
  • Bayou City Research, Ltd.
    Houston, Texas 77007, United States
  • Red Oak Psychiatry Associates P.A.
    Houston, Texas 77090, United States
  • John M. Turnbow, MD, PA
    Lubbock, Texas 79423, United States
  • Vermont Clinical Study Center
    Burlington, Vermont 05401, United States
  • Neuropsychiatric Associates
    Woodstock, Vermont 05091, United States
  • Neuroscience, Inc
    Herndon, Virginia 20170, United States
  • Eastside Therapeutic Resource
    Kirkland, Washington 98033, United States
  • Summit Research Network, LLC
    Seattle, Washington 98104, United States
  • Rockwood Clinic
    Spokane, Washington 99202, United States
  • Dean Foundation for Health, Research and Education
    Middleton, Wisconsin 53562, United States
09

References and documents

Publications

  • Adler LA, Dirks B, Deas PF, Raychaudhuri A, Dauphin MR, Lasser RA, Weisler RH. Lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder who report clinically significant impairment in executive function: results from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2013 Jul;74(7):694-702. doi: 10.4088/JCP.12m08144. PubMed 23945447 ↗
  • Brown TE, Chen J, Robertson B. Relationships Between Executive Function Improvement and ADHD Symptom Improvement With Lisdexamfetamine Dimesylate in Adults With ADHD and Executive Function Deficits: A Post Hoc Analysis. Prim Care Companion CNS Disord. 2020 May 28;22(3):19m02559. doi: 10.4088/PCC.19m02559. PubMed 32470230 ↗
  • Adler LA, Dirks B, Deas P, Raychaudhuri A, Dauphin M, Saylor K, Weisler R. Self-Reported quality of life in adults with attention-deficit/hyperactivity disorder and executive function impairment treated with lisdexamfetamine dimesylate: a randomized, double-blind, multicenter, placebo-controlled, parallel-group study. BMC Psychiatry. 2013 Oct 9;13:253. doi: 10.1186/1471-244X-13-253. PubMed 24106804 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2010 to primary completion in Nov 2010, 6 months.

Results were first posted in Feb 2012, 1 year 2 months after primary completion.

Of 62 phase 4 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 70. This study's 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2010
First posted
Apr 9, 2010
StartActual
May 19, 2010
Primary completionActual
Nov 29, 2010
CompletionActual
Nov 29, 2010
Results first posted
Feb 13, 2012
Last update
Jun 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01101022
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Apr 9, 2010
Start date
May 19, 2010
Primary completion
Nov 29, 2010
Completion
Nov 29, 2010
Results posted
Feb 13, 2012
Last update
Jun 9, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lisdexamfetamine

Start the discussion